Prime editing depends on a long guide RNA - the pegRNA - that is fragile and quickly degraded inside the cell. US11884915B2 - "Guide RNAs with chemical modification for prime editing," issued January 30, 2024 to Agilent Technologies, Inc. - claims the chemistry that keeps it intact.
The load-bearing limitation is the chemical modification. A prime editing guide RNA (pegRNA) is longer and more structured than an ordinary single guide, which makes it more vulnerable to nuclease degradation. The claim recites specific chemical modifications - to the backbone and termini - that stabilize the pegRNA and improve editing efficiency. The prime-editing system is the context; the modifications are the invention.
The CPC tags pinpoint it: C12N 15/102 (editing method) for context, but the operative tags are C12N 2310/315, C12N 2310/321 (sugar and backbone modifications) - the RNA-chemistry classes. When a guide-RNA patent's distinguishing CPC tags are modification classes, the claim is a chemistry claim, not an editing-architecture claim.
Why does this matter for scope and ownership? Because prime editing's foundational architecture is held upstream (the Broad / Liu estate), but the enabling chemistry that makes pegRNAs practical is a separate, separately-ownable contribution. Agilent's position is in the modification chemistry - a complement to, not a substitute for, the architecture patents. A prime-editing program may need both.
For the landscape, modified-pegRNA grants are part of the practical-enablement layer that turns a laboratory technique into a usable therapeutic tool. Freedom-to-operate for a prime-editing therapy means clearing the architecture (Broad), the improvements like dual-strand editing (Broad), and the guide-RNA chemistry (Agilent and others) - three distinct layers, each separately owned.